Flunarizine dihydrochloride
SIGMA/F8257 - ≥98% (TLC)
Synonym: 1-
CAS Number: 30484-77-6
Empirical Formula (Hill Notation): C26H26F2N2 · 2HCl
Molecular Weight: 477.42
EC Number: 250-216-6
MDL Number: MFCD00058198
Linear Formula: C26H26F2N2 · 2HCl
Product Type: Chemical
| assay | ≥98% (TLC) |
| InChI | 1S/C26H26F2N2.2ClH/c27-24 |
| InChI key | RXKMOPXNWTYEHI-RDRKJGRWSA |
| originator | Johnson & Johnson |
| Quality Level | 200 ![]() |
| SMILES string | Cl[H].Cl[H].Fc1ccc(cc1)C( |
| storage temp. | 2-8°C |
| Application: | Flunarizine dihydrochloride has been used to study the effect of flunarizine on epileptiform activity. It is also used to study its effect on high-potassium induced increase of intracellular free calcium. |
| Biochem/physiol Actions: | Blocks T-type Ca2+/Na+ channels. |
| Biochem/physiol Actions: | Blocks T-type Ca2+/Na+ channels; inhibits K+-induced catecholamine release from chromaffin cells |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Flunarizine has antihistamine, anticonvulsant and vestibular depressive properties. It protects endothelial cells from calcium overload-induced damage. Flunarizine is used to treat epilepsy, migraine prophylaxis, cerebral blood flow disturbances, peripheral vascular disease and vertigo. |
| Packaging: | 1, 10 g in poly bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264 - P270 - P301 + P312 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (TLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


